Document Detail


Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis.
MedLine Citation:
PMID:  1446494     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy of ofloxacin, rifampicin and isoniazid was prospectively compared with the regimen of ethambutol, rifampicin and isoniazid for the primary treatment of pulmonary tuberculosis in 124 patients. All drugs were given orally daily for nine months. Culture conversion rates three months after starting treatment were 98 percent in the ofloxacin group and 94 percent in the ethambutol group; by six months all patients in both groups were culture-negative. Significant radiological improvement of pulmonary infiltrates was observed in 83 percent of the ofloxacin group and 85 percent of the ethambutol group one year after starting treatment. No relapse in either group was observed during a two-year follow-up period after the cessation of chemotherapy. Ofloxacin appears to be as useful as ethambutol in the treatment of pulmonary tuberculosis when either drug is combined with isoniazid and rifampicin.
Authors:
S Kohno; H Koga; M Kaku; S Maesaki; K Hara
Related Documents :
7099244 - Coccidioidomycosis: evaluation of parameters used to predict outcome with amphotericin ...
3100354 - Ketoconazole treatment of 13 patients with chronic mucocutaneous candidiasis. a prospec...
14991514 - Comparison of clinical features in patients with pulmonary mycobacterium-avium complex ...
17954324 - The impact of dental surgery on hsv-1 reactivation in the oral mucosa of seropositive p...
14563144 - Low-dose radiotherapy for the inhibition of peridural fibrosis after reexploratory nerv...
10577584 - Long-term follow-up of trabeculectomy without antimetabolites in patients with uveitis.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Chest     Volume:  102     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  1992 Dec 
Date Detail:
Created Date:  1992-12-29     Completed Date:  1992-12-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1815-8     Citation Subset:  AIM; IM    
Affiliation:
Second Department of Internal Medicine, Nagasaki University School of Medicine, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Drug Combinations
Drug Resistance, Microbial
Ethambutol / administration & dosage,  adverse effects,  therapeutic use*
Female
Humans
Isoniazid / administration & dosage,  therapeutic use
Male
Middle Aged
Mycobacterium tuberculosis / drug effects,  isolation & purification
Ofloxacin / administration & dosage,  adverse effects,  therapeutic use*
Prospective Studies
Rifampin / administration & dosage,  therapeutic use
Time Factors
Tuberculosis, Pulmonary / drug therapy*,  microbiology
Chemical
Reg. No./Substance:
0/Drug Combinations; 13292-46-1/Rifampin; 54-85-3/Isoniazid; 74-55-5/Ethambutol; 82419-36-1/Ofloxacin
Comments/Corrections
Comment In:
Chest. 1994 May;105(5):1624   [PMID:  8181387 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Human pleural effusions are rich in matrix metalloproteinases.
Next Document:  Diagnostic value of sialic acid in malignant pleural effusions.